Publication | Closed Access

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

Primary Systemic TreatmentBreast OncologyOncologyPhase Ii TrialEndocrine-related CancerMedicineClinical TrialsGynecologyBreast CancerMenopausePharmacotherapyMenopause Hormone TherapyEndocrinologyPharmacologyRadiation OncologyCancer ResearchAustrian BreastHealth Sciences